The results also show that the expression of FGL2 in the model group was significantly increased, while FGL2 content decreased in the group treated with CMZ (P < 0.05, Fig. 6D), which suggested that the inhibitory effect of the CYP2E1 inhibitor on the liver cancer mouse model may be related to the decreased expression of FGL2. The gene discussed is CYP2E1; the disease is liver cancer.